Dr Darrin M Disley Obe Email & Phone Number

United Kingdom

London, Gb

Roquefort Therapeutics plc was established to acquire businesses focused on early-stage drug development opportunities in the medical biotechnology sector with the aim of developing a pipeline of therapies that ultimately generate optimal returns for both the target businesses and our shareholders.Roquefort is listed on the main market of the London Stock Exchange under the ticker ROQ.

Cambridge, Cambridgeshire, Gb

Advisory board member of Sana Capital a new, female-led investment fund supporting innovation in science and technology that will drive positive change in human healthcare.

Cambridge, Cambridgeshire, Gb

CEO responsible for corporate strategy, execution and governance. Mogrify has developed a proprietary systematic data-science driven cell conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the key transcriptomic and/or epigenetic switches that control human cell fate. Mogrify is applying its technology to generate IP and cell conversions that will power the development and manufacture of a new class of in vivo reprogramming therapies for chronic degenerative diseases of the ear, eye, pancreas and lung.Seed/A/Grant funding of $50M raised in 2019/20/21/23.

Cardiff, Wales, Gb

Investor and Chairman of the Board of Directors of regenerative medicine company founded by Nobel Prize winner for Sir Martin Evans. Phase 2 clinical trial stage with lead HeartCel product plus oncology and orthopaedic cell therapy assets.Funding of c$30M raised in 2015/22, Contingent PIPE funding of $100M in place.Demerged oncology pipeline acquired by Roquefort Therapeutics Plc in September 2022

Investor in portfolio of companies in IT, Tech and Life Science sectors.

Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Cambodia which now employs 17 staff and has generated and donated 100% of its profits to eight local organizations tackling illiteracy, gender inequality and community development.

Salford, Greater Manchester, Gb

Honorary Visiting Fellow of The School of Environmental and Life Sciences. Providing strategic and industrial context to researchers as well as access to networks in Life Sciences. Ambassadorial role promoting the activities of the School.

Cambridge, Gb

Honorary Fellowship supporting the research, teaching, fundraising and ambassadorial activities of the school.

Cambridge, Gb

Invited lecturer, course content provider and mentor on various higher education programs and courses.

Cambridge, England, Gb

Invited lecturer and mentor at the Department of Chemical Engineering and Biotechnology.

Award of needs based bursaries and hardship grants, funding, mentorship, student entrepreneurship activities (Cambridge University Entrepreneurs, Cambridge University Technology and Enterprise Club) and emerging start-up companies.

London, Gb

Elected board member of organisation whose mission is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. The BIA binds the community together, serving as its voice with stakeholders, lobbying government and regulatory bodies, building connections between individuals and organisations, helping to shape the future of bioscience.

Cambridge, Cambridgeshire, Gb

Advisor on commercial and operations strategy to company using AI driven platform to intelligently match drugs to patients of rare diseases. Winner CR Lowe Carpe Diem Enterprise Life Science Start-up of Year 2015; Seed Funding of c$500k raised 2015; Series A Funding of C$13M raised 2016, 2018. Series B Funding of $55M raised in 2019.

Cambridge, England, Gb

Member of not-for-profit Board that both guides organizational direction and supports financially the Cambridge Science Center an exhibition centre that works locally and regionally (via mobile exhibitions) to engage children and families through hands on science exhibits, shows and workshops.

Cambridge, Cambridgeshire, Gb

Advisor on commercial and operational strategy to Social Enterprise.Winner of CR Lowe Enterprise Funded Cambridge University Entrepreneurs Social Enterprise of the Year 2014.Seed Funded by Arm and Bill and Melinda Gates Foundation and various grant bodies. $8M raised.

Cambridge, Cambridgeshire, Gb

Advisor on corporate development, business strategy and investor relations for company operating in the reprogramming of stem cells to create novel research tools. Investor.Co-lead investor on Series A Funding Raised of £1M in 2016.Series B Raised of £3M in 2017.

London, London, Gb

Member of board advising publication that aims to provide closer ties between bioscience, investors, pharma, financiers, customers, legal and professional advisers.

Seed Investor and mentor to founder of UK biotechnology company engaged in the use of a proprietary cell reprogramming platform to create consistent, pure and evergreen supply of primary human cell types.£300k seed (2016); £6M Seed Extension (2019); £30M A (2020); £65M B (2021)

Established as a joint-venture between Horizon Discovery Group Plc and Centauri Therapeutics Avvinity is developing novel cancer immunotherapies based on proprietary Alphamer technology invented by Cary Mullis, Nobel Prize winner for invention of PCR. £3M seed funding committed in 2016.

Cambridge, Cambridgeshire, Gb

CEO of global life science company supplying research tools, contract research services and novel research programs that impact translational genomics research, personalized medicine and cell therapy.Pre-IPO Funding c$30M Raised 2008-2013; Post IPO Funding c$180M (Primary) and c$90M (Secondary) placements. Market Capitalization high in 2017 of c$560M. Has delivered 2X to 50X return on investment for investors.

Cambridge, Gb

Advisor on corporate development, business strategy and investor relations. Lead Investor Seed and A Round.Winner CR Lowe Carpe Diem Enterprise Young Entrepreneur of the Year (Steve Marsh) of Year 2012; Seed Funding Raised of $2.5M in 2013-14Series A Funding Raised of $40M in 2015-2020. Chairman Feb 2013 to Sept 2016Non-Executive Director Feb 2013 to Nov 2017

Cambridge, Massachusetts, Us

Advisor on corporate development, business strategy and investor relations. Lead Investor Seed Round.Winner CR Lowe Carpe Diem Enterprise Life Science Start-up of Year 2012; Seed Funding of $3M raised over 2013/2015.

CEO and co-founder of biotech company with Scientific Generics Plc, Imperial College and University of Glasgow. Company engaged in R&D aimed at developing protein array, cell chip and predictive bioinformatics platform to enable the implementation of advanced molecular profiling of drug candidates.c$2M funding raised 2001-02

Melbourn, Hertfordshire, Gb

Responsible for managing the Bioscience R&D program of the Acumen High Content Screening consortia comprising and funded by AstraZeneca, Aventis and TTP. Along with senior leadership raised non-dilutive funding of the program and headed the successful launch of the Acumen Explorer in 2000, a platform that still sells today (sold to Danehar 2019).

Doctor Of Philosophy (Phd), Biotechnology

Doctor Of Science (Honoris Causa), Business, Enterprise And Healthcare

Bachelor Of Science (Bsc), Chemistry

Onc, Science

No Qualifications Obtained.